Decline in Lung Cancer Mortality Affects Decreases in Overall Cancer Deaths
Reductions in lung cancer mortality are driving the steady decline in overall cancer deaths.
Lung Cancer
LUNG CANCER
FEATURED
LATEST FEATURES
Lung Cancer Screening: Rates Remain Low and Disparities Run High
Despite resources, lung cancer screening with low-dose computed tomography remains underutilized.
Vaping Injuries Raise New Concerns About Medical Marijuana
Many recent vaping injuries have been linked to e-cigarette use of THC oils or other cannabis oil products, raising new concerns about patients with cancer who use the devices for medical marijuana.
Pharmacovigilance Needed for Immune Checkpoint Inhibitor Therapy in NSCLC
Immune checkpoint inhibitor therapies have improved survival in patients with non-small cell lung cancer, but they have also been linked to immune-related adverse events affecting various organs, including the lungs.
LATEST NEWS
Novel Bispecific Antibody Gets Breakthrough Therapy Status for NSCLC
The FDA has granted Breakthrough Therapy designation to JNJ-6372 for the treatment of patients with NSCLC with EGFR Exon 20 insertion mutations.
Brigatinib Receives Priority Review for First-Line Treatment of ALK+ Metastatic NSCLC
The Food and Drug Administration has granted Priority Review for the supplemental New Drug Application (sNDA) for brigatinib (Takeda) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).
Atezolizumab Monotherapy Under Review for First-Line Advanced NSCLC Treatment
The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for atezolizumab (Tecentriq®; Genentech) as a first-line monotherapy in patients with advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations with high PD-L1 expression (TC3/IC3 wild-type [WT]), as determined by PD-L1 biomarker testing.
Lurbinectedin Under Review for Relapsed Small Cell Lung Cancer
The FDA has accepted for Priority Review the NDA for lurbinectedin for the treatment of patients with small cell lung cancer who have progressed after prior platinum-containing therapy.
Lung Cancer Mortality in Former Smokers Reduced With Low-Dose CT Screening
Volume-based, low-dose computed tomographic screening at various intervals may reduce the risk of lung cancer mortality in people who were current smokers or had a history of smoking.
Want to read more?
Please login or register first to view this content.
Next post in Lung Cancer
